BioCentury | May 17, 2019
Financial News

Actuate gets $21.7M to expand clinical testing of lead candidate

...it a viable target. Actuate President and CEO Daniel Schmitt told BioCentury that lead candidate 9-ING-41...
...a $3.8 million series A in 2017 from Bios Partners and IllinoisVENTURES. Elizabeth S. Eaton, Staff Writer 9-ING-41 Actuate...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Neurology

...to treat Parkinson’s disease. Actuate Therapeutics Inc. has submitted an IND for the GSK3B inhibitor 9-ING-41...
BioCentury | May 16, 2018
Distillery Therapeutics

Neurology

...and amyotrophic lateral sclerosis. Actuate Therapeutics Inc. has submitted an IND for the GSK3B inhibitor 9-ING-41...
Items per page:
1 - 3 of 3